Lecture

management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.

Giuseppe Procopio, Monica Niger, Isabella Testa

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

Original languageEnglish
JournalNeurological Sciences
Volume32 Suppl 2
Publication statusPublished - Nov 2011

Fingerprint

Chemotherapy-Induced Febrile Neutropenia
Colony-Stimulating Factors
Febrile Neutropenia
Guidelines
Granulocyte Colony-Stimulating Factor
Radiotherapy
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lecture : management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. / Procopio, Giuseppe; Niger, Monica; Testa, Isabella.

In: Neurological Sciences, Vol. 32 Suppl 2, 11.2011.

Research output: Contribution to journalArticle

@article{19b8059d1c524ea98bba33626e4c48aa,
title = "Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.",
abstract = "Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20{\%}, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20{\%} risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20{\%}). In case of low risk of FN (",
author = "Giuseppe Procopio and Monica Niger and Isabella Testa",
year = "2011",
month = "11",
language = "English",
volume = "32 Suppl 2",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Lecture

T2 - management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors.

AU - Procopio, Giuseppe

AU - Niger, Monica

AU - Testa, Isabella

PY - 2011/11

Y1 - 2011/11

N2 - Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

AB - Chemotherapy-induced febrile neutropenia (FN) is a major risk factor for severe infections potentially fatal, and also a dose-limiting toxicity, so causing dose reductions and/or delays in scheduled chemotherapy. This lecture provides recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. If expected risk of FN is equal or superior to 20%, a primary prophylaxis of FN with G-CSF is recommended. Primary prophylaxis can be considered in case of intermediate 10-20% risk of FN, in presence of factors that increase the frequency/risk of FN, such as age >65, advanced disease, prior episode of FN, poor performance status, radiotherapy to a wide body area (>20%). In case of low risk of FN (

UR - http://www.scopus.com/inward/record.url?scp=84859461151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859461151&partnerID=8YFLogxK

M3 - Article

VL - 32 Suppl 2

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -